We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.71%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$810M
AUM Growth
-$260M
Cap. Flow
-$189M
Cap. Flow %
-23.28%
Top 10 Hldgs %
32%
Holding
105
New
11
Increased
30
Reduced
42
Closed
19

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$17.2M
2
VEEV icon
Veeva Systems
VEEV
+$16.8M
3
BSX icon
Boston Scientific
BSX
+$15.5M
4
ABT icon
Abbott
ABT
+$12.6M
5
WAY
Waystar Holding Corp
WAY
+$9.09M

Top Sells

Rank Stock Value
1
COO icon
Cooper Companies
COO
+$22M
2
VERA icon
Vera Therapeutics
VERA
+$21.3M
3
MDT icon
Medtronic
MDT
+$19.7M
4
DHR icon
Danaher
DHR
+$17.2M
5
ALGN icon
Align Technology
ALGN
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
101
Rhythm Pharmaceuticals
RYTM
$7.26B
– –
-35,000
Closed -$3.75M
TGTX icon
102
TG Therapeutics
TGTX
$7.46B
– –
-73,250
Closed -$2.18M
VERA icon
103
Vera Therapeutics
VERA
$2.15B
– –
-420,000
Closed -$21.3M
WST icon
104
West Pharmaceutical
WST
$24.5B
– –
-7,000
Closed -$1.93M
XNCR icon
105
Xencor
XNCR
$1.48B
– –
-165,750
Closed -$2.54M
1 2 3 4
5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rhenman & Partners Asset Management held 105 positions worth $810M, down 24% from $1.07B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $189M in Q1 2026, closing 19 positions and reducing 42 holdings. Its most notable exit was Vera Therapeutics, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Stryker worth $15.7M.

  • Rhenman & Partners Asset Management's largest Q1 2026 buy was Stryker: 47,800 shares worth $15.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q1 2026, an estimated $15.5M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2026 reduction was Cooper Companies, cutting an estimated $22M.
  • Rhenman & Partners Asset Management fully exited Vera Therapeutics in Q1 2026, selling an estimated $21.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $810M portfolio in Q1 2026.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 19 in Q1 2026.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $810M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.